Top 3 Health Care Stocks That May Keep You Up At Night In Q1

Benzinga08:55 ET

Novo Nordisk's Combo Drug CagriSema Shows 16% Weight Reduction In Second Phase 3 Trial

Benzinga08:35 ET

Halia Therapeutics Awarded Novo Nordisk Golden Ticket to Advance Obesity and Inflammation Research

PR Newswire08:00 ET

BofA Keeps Novo Nordisk at Buy Despite 'Disappointing' CagriSema Weight-loss Data

MT Newswires07:59 ET

Can Novo-Nordisk A/S (NVO.US) rely on the new weight loss drug CagriSema to compete with Eli Lilly and Co?

The battle for the global weight loss drug market is heating up, with the latest data from Novo-Nordisk A/S's Phase III clinical trial of CagriSema sparking intense debate among institutions.

Zhitong Finance07:54 ET

Ozempic's New Frontier: The War on Aging -- WSJ

WSJ21:00 ET